The following is an excerpt from a S-1 SEC Filing, filed by XCEL PHARMACEUTICALS INC on 1/7/2002.
-- Use Sections To Navigate Through The Document --
FORM S-1
CALCULATION OF REGISTRATION FEE
SUBJECT TO COMPLETION, DATED JANUARY 6, 2002.
TABLE OF CONTENTS
PROSPECTUS SUMMARY
The Offering
RISK FACTORS
INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
USE OF PROCEEDS
DIVIDEND POLICY
CAPITALIZATION
DILUTION
BENEFICIAL OWNERS
SELECTED FINANCIAL DATA
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
Liquidity and Capital Resources
Quantitative and Qualitative Disclosure About Market Risks
BUSINESS
Competition
Employees
Legal Proceedings
MANAGEMENT
NAME AND TITLE
Director Compensation
Compensation Committee Interlocks and Insider Participation
Executive Compensation
COMPENSATION TABLE
OPTIONS
Stock Plans
RELATED-PARTY TRANSACTIONS
PRINCIPAL STOCKHOLDERS
BENEFICIAL OWNERS
DESCRIPTION OF CAPITAL STOCK
Transfer Agent and Registrar
SHARES ELIGIBLE FOR FUTURE SALE
Eligibility of Restricted Shares for Sale in the Public Market
UNDERWRITING
LEGAL MATTERS
EXPERTS
WHERE YOU CAN FIND MORE INFORMATION
INDEX TO FINANCIAL STATEMENTS
INDEPENDENT AUDITORS' REPORT
BALANCE SHEET
INCOME STATEMENT
STOCKHOLDERS EQUITY
CASH FLOW
NOTES TO FINANCIAL STATEMENTS
BALANCE SHEET
INDEPENDENT AUDITORS' REPORT
INDEPENDENT AUDITORS' REPORT
PART II
Item 13. Other Expenses of Issuance and Distribution
Item 14. Indemnification of Directors and Officers
Item 15. Recent Sales of Unregistered Securities
Item 16. Exhibits and Financial Statement Schedules
Item 17. Undertakings
SIGNATURES
POWER OF ATTORNEY
EXHIBIT INDEX
EXHIBIT 3.1
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
EXHIBIT 3.3
BYLAWS
EXHIBIT 3.5
EXHIBIT 3.6
EXHIBIT 4.2
EXHIBIT 4.3
EXHIBIT 4.4
EXHIBIT 4.6
EXHIBIT 10.1
EXHIBIT 10.2
EXHIBIT 10.3
EXHIBIT 10.4
EXHIBIT 10.5
EXHIBIT 10.6
EXHIBIT 10.7
EXHIBIT 10.8
EXHIBIT 23.1
INDEPENDENT AUDITORS' CONSENT
EXHIBIT 23.3
CONSENT OF ERLE T. MAST
XCEL PHARMACEUTICALS INC - S-1 - 20020107 - TABLE_OF_CONTENTS
TABLE OF CONTENTS
Page
1
5
14
14
15
15
16
17
18
20
25
35
42
43
45
48
50
52
52
53
F-1
Until and including
, 2002 (25 days after the date of this prospectus), all dealers that buy, sell or trade our common stock, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to the dealers obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.